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Introduction
Diagnosed sexually transmitted infections (STIs) have 
increased substantially in Britain (England, Scotland, 
and Wales) since the 1990s1 and throughout the past 
decade to the end of 2012,2 emphasising the importance 
of sustained public health programmes to identify and 
treat infections, reduce morbidity and mortality, and 
prevent onward transmission. Population-based 
estimates of infection prevalence, risk distribution, and 
intervention uptake inform the design and delivery of 
STI control programmes. The National Surveys of Sexual 
Attitudes and Lifestyles (Natsal)-1 (1990–91) and Natsal-2 
(1999–2001) have guided the development of sexual 
health programmes by providing empirical evidence to 
understand the heterogeneity of sexual behaviour in the 
British population,3,4 the prevalence of STIs, and the 
drivers of transmission.5,6 Surveillance of STI diagnoses 
does not measure the true prevalence of STIs in the 
population because infections are often asymptomatic 
and undiagnosed. Natsal links prevalence (measured 
with biological sampling) with population risk 
factors and can thus assess the extent to which infected 
and at-risk individuals access speciﬁ c interventions 
and services.
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Summary
Background Population-based estimates of prevalence, risk distribution, and intervention uptake inform delivery of 
control programmes for sexually transmitted infections (STIs). We undertook the third National Survey of Sexual 
Attitudes and Lifestyles (Natsal-3) after implementation of national sexual health strategies, and describe the 
epidemiology of four STIs in Britain (England, Scotland, and Wales) and the uptake of interventions.
Methods Between Sept 6, 2010 and Aug 31, 2012, we did a probability sample survey of 15 162 women and men aged 
16–74 years in Britain. Participants were interviewed with computer-assisted face-to-face and self-completion 
questionnaires. Urine from a sample of participants aged 16–44 years who reported at least one sexual partner over the 
lifetime was tested for the presence of Chlamydia trachomatis, type-speciﬁ c human papillomavirus (HPV), Neisseria 
gonorrhoeae, and HIV antibody. We describe age-speciﬁ c and sex-speciﬁ c prevalences of infection and intervention uptake, 
in relation to demographic and behavioural factors, and explore changes since Natsal-1 (1990–91) and Natsal-2 (1999–2001).
Findings Of 8047 eligible participants invited to provide a urine sample, 4828 (60%) agreed. We excluded 278 samples, 
leaving 4550 (94%) participants with STI test results. Chlamydia prevalence was 1·5% (95% CI 1·1–2·0) in women 
and 1·1% (0·7–1·6) in men. Prevalences in individuals aged 16–24 years were 3·1% (2·2–4·3) in women and 2·3% 
(1·5–3·4) in men. Area-level deprivation and higher numbers of partners, especially without use of condoms, were 
risk factors. However, 60·4% (45·5–73·7) of chlamydia in women and 43·3% (25·9–62·5) in men was in individuals 
who had had one partner in the past year. Among sexually active 16–24-year-olds, 54·2% (51·4–56·9) of women and 
34·6% (31·8–37·4) of men reported testing for chlamydia in the past year, with testing higher in those with more 
partners. High-risk HPV was detected in 15·9% (14·4–17·5) of women, similar to in Natsal-2. Coverage of HPV 
catch-up vaccination was 61·5% (58·2–64·7). Prevalence of HPV types 16 and 18 in women aged 18–20 years was 
lower in Natsal-3 than Natsal-2 (5·8% [3·9–8·6] vs 11·3% [6·8–18·2]; age-adjusted odds ratio 0·44 [0·21–0·94]). 
Gonorrhoea (<0·1% prevalence in women and men) and HIV (0·1% prevalence in women and 0·2% in men) were 
uncommon and restricted to participants with recognised high-risk factors. Since Natsal-2, substantial increases were 
noted in attendance at sexual health clinics (from 6·7% to 21·4% in women and from 7·7% to 19·6% in men) and 
HIV testing (from 8·7% to 27·6% in women and from 9·2% to 16·9% in men) in the past 5 years.
Interpretation STIs were distributed heterogeneously, requiring general and infection-speciﬁ c interventions. 
Increases in testing and attendance at sexual health clinics, especially in people at highest risk, are encouraging. 
However, STIs persist both in individuals accessing and those not accessing services. Our ﬁ ndings provide empirical 
evidence to inform future sexual health interventions and services.
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Since Natsal-2, several strategies to improve sexual 
health have been implemented in Britain, as they have 
been in other developed countries or regions.7–12 The 
British initiatives include the National Strategy for Sexual 
Health and HIV in England (2001);13 Respect and 
Responsibility: Strategy and Action Plan for Improving 
Sexual Health in Scotland (2005);14 and the Strategic 
Framework for Promoting Sexual Health in Wales (2001).15 
All the strategies have broad sexual health objectives and 
promote a reduction in risk behaviour (eg, increased 
condom use). Three STI-speciﬁ c interventions have been 
implemented: (1) the English National Chlamydia 
Screening Programme (NCSP) in 2003 (opportunistic 
screening in sexually active women and men aged 
16–24 years); Scottish and Welsh strategies encouraged 
testing in this age group, but with no formal programme; 
(2) the UK human papillomavirus (HPV) immunisation 
programme in 2008, using the bivalent HPV 16/18 vaccine 
(routine immunisation of girls aged 12–13 years, with a 
catch-up programme up to age 17 years); and (3) strategies 
to increase HIV testing in target groups as outlined in the 
2008 British HIV Association (BHIVA) National 
Guidelines.16 Furthermore, the range and accessibility of 
STI services has broadened, with modernised sexual 
health (genitourinary medicine [GUM]) clinics, targets for 
48 h waiting times, and expansion of the role of primary 
care.
We present age-speciﬁ c and sex-speciﬁ c estimates for 
the population prevalence of, and associated risk factors 
for, infection with Chlamydia trachomatis, high-risk HPV, 
Neisseria gonorrhoeae, and HIV from a probability sample 
of 16–44-year-olds in Britain. Additionally, we describe 
the uptake of interventions and sexual health services, 
and explore changes since Natsal-1 and Natsal-2.
Methods
Participants and procedures
Natsal-3 is a stratiﬁ ed probability sample survey of 
15 162 women and men aged 16–74 years in Britain who 
were interviewed between Sept 6, 2010, and Aug 31, 2012. 
The estimated overall response rate was 57·7% and the 
cooperation rate was 65·8% (of all eligible addresses 
contacted). Participants were interviewed with a 
combination of computer -assisted face-to-face and self-
completion questionnaires, which included questions 
about participants’ sexual lifestyles and attitudes, and 
questions about STIs, including attendance at sexual 
health clinics, previous STI diagnoses, previous STI or 
HIV tests, STI symptoms, and HPV vaccination. 
Whenever possible, questions used were consistent 
between all three Natsal studies, with new or changed 
questions included after cognitive testing.17 However, the 
wording of the question about clinic attendance was 
changed in accordance with changes in terminology 
used in sexual health services. Participants in Natsal-1 
and Natsal-2 were asked “Have you ever attended a 
sexually transmitted disease clinic or special (VD) clinic?” 
Participants in Natsal-3 were asked “Have you ever 
attended a sexual health clinic (GUM clinic)?”. Full 
details of the methods have been described elsewhere.18–20 
An anonymised dataset will be deposited with the UK 
Data Archive and the complete questionnaire and 
technical report will be available on the Natsal website on 
the day of publication.
After the interview, we invited a sample of participants 
aged 16–44 years (all participants aged 16–17 years; all 
those aged 18–24 years who reported at least one sexual 
partner over the lifetime; a random subsample of 85% of 
25–44-year-olds who reported at least one sexual partner 
over the lifetime; and any remaining men aged 25–44 years 
who reported having sex with another man in the past 
5 years) to provide a urine sample for STI testing. We used 
this strategy to maximise information from groups in 
whom morbidity and interventions are concentrated, with 
considerations of sample-size calculations and appropriate 
use of resources. Urine was collected with the FirstBurst 
device, which collects the ﬁ rst 4–5 mL of voided urine, 
thus yielding a higher load of C trachomatis than the 
regular urine cup,21 which, on the basis of development 
work for Natsal-3, might also increase detection of HPV 
DNA and HIV antibody.19 Samples were posted to Public 
Health England for testing. All participants were given 
information about where to obtain free diagnostic STI and 
HIV testing and sexual health advice.
In view of the low population prevalence of some STIs, 
our predeﬁ ned testing strategy aimed to reduce the 
likelihood of false positives. Detection of C trachomatis and 
N gonorrhoeae was done with the Aptima Combo 2 assay 
(Hologic Gen-Probe) as an initial screen, and we conﬁ rmed 
all positive and equivocal results with the Aptima 
monospeciﬁ c assays for detection of C trachomatis or 
N gonorrhoeae. We used an in-house Luminex-based 
genotyping assay to detect HPV types.22 We deﬁ ned high-
risk types as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
68.23 We identiﬁ ed HIV infection with a modiﬁ ed IgG 
antibody-capture particle-adherence test (GACPAT)24 to 
detect HIV-1 and HIV-2 antibodies in urine;25 we conﬁ rmed 
results with HIV western blot 2.2 (MP Biomedicals, UK).
Statistical analysis
We did all statistical analyses with Stata (version 12.1), 
accounting for stratiﬁ cation, clustering, and weighting of 
the sample. We included an additional weight, derived 
from a logistic regression model, which corrected for 
unequal probabilities of urine-sample selection, and 
diﬀ erential sample response.19 Generally, before 
weighting, younger individuals; those who had had same-
sex relationships; and those who engaged in high-risk 
behaviours, such as more partners with whom they had 
unprotected sex, were more likely to provide a urine 
sample than were other participants. We present 
prevalence estimates in women and men, by age group, 
with 95% CIs, in participants who reported at least one 
sexual partner over the lifetime. We examined the 
For the NCSP see http://www.
chlamydiascreening.nhs.uk/ 
For more on the HPV 
immunisation programme see 
http://www.nhs.uk/Conditions/
vaccinations/Pages/hpv-human-
papillomavirus-vaccine.aspx
For the questionnaire and more 
information on Natsal-3 see 
http://www.natsal.ac.uk/
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associations between chlamydia and high-risk HPV and 
demographic and behavioural variables with logistic 
regression and present crude odds ratios (ORs) and 
adjusted ORs (AORs). Multivariable analyses adjusted for 
two demographic variables (age and area-level deprivation 
[index of multiple deprivation; IMD])26 and one behavioural 
factor (number of sexual partners in the past year; a key 
factor in STI epidemiology and a useful indicator for 
sexual health-care providers). We considered IMD to be 
an important predictor and possible confounder, because 
services and interventions are often commissioned and 
provided on an area-level basis. We present uptake of 
interventions by risk factors or target groups, in the 
relevant age ranges of participants aged 16–44. We 
compared these ﬁ ndings, when possible, across the three 
surveys. We estimated the annual rate of chlamydia 
diagnosis per 100 000 population (an indicator in the 
Public Health Outcomes Framework for England)27 from 
self-reported chlamydia diagnoses in the past year in all 
participants aged 16–24 years living in England. We report 
coverage of HPV vaccination in women who reported any 
sexual experience and were eligible for the HPV catch-up 
immunisation programme (ie, were born between Sept 1, 
1990, and Aug 31, 1995). We obtained ethics approval from 
Oxfordshire Research Ethics Committee A (reference 09/
H0604/27). Participants gave written informed consent to 
anonymised testing, without the return of results, the 
ethical rationale for which has been previously described.28 
Details about the preparation, testing, and quality 
assurance of urine samples have been published 
elsewhere.18,19
Role of funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of 9902 participants aged 16–44 years, 8947 (90%) 
reported at least one sexual partner over the lifetime. Of 
these individuals, 8047 (90%) were invited to provide a 
urine sample of whom 4828 (60%) agreed. We excluded 
278 samples (on the basis of insuﬃ  cient samples, 
mislabelling, or unrecorded consent), leaving 4550 (94%) 
participants with STI test results (2665 women and 
1885 men).
98 participants (62 women and 36 men) tested positive 
for chlamydia. Table 1 shows the weighted age-speciﬁ c 
prevalences in women and men. For women, the highest 
prevalence was in those aged 18–19 years (table 1). By 
contrast, for men, the highest prevalence was in those 
aged 20–24 years (table 1). We detected no positive 
chlamydia tests in men aged 16–17 years and few positives 
in those aged 18–19 years (table 1). Individuals living in 
the most deprived regions were more likely to test positive 
for chlamydia (table 2). Prevalence of chlamydia increased 
with increasing numbers of partners in the past year 
(table 2). However, an estimated 60·4% (95% CI 
45·5–73·7%) of prevalent chlamydia in women, and 
43·3% (25·9–62·5%) in men, was in those with only one 
partner in the past year. Reporting of two or more partners 
without use of a condom in the past year was more 
strongly associated with chlamydia than were partner 
numbers alone (table 2).
Prevalence of chlamydia in participants aged 
16–24 years—ie, the age group targeted by the NCSP—
was 3·1% (2·2–4·3%) in women and 2·3% (1·5–3·4%) 
in men. Women aged 16–24 years were more likely to 
Age 16–17 years Age 18–19 years Age 20–24 years Age 25–34 years Age 35–44 years All ages
Women
Chlamydia trachomatis 2·3% (0·9–5·8) 4·7% (2·5–8·6) 2·7% (1·7–4·2) 1·5% (0·9–2·5) 0·3% (0·1–1·3) 1·5% (1·1–2·0)
Human papillomavirus*
High–risk types 16·3% (11·1–23·4) 29·6% (23·5–36·5) 26·6% (22·8–30·8) 15·6% (13·4–18·2) 9·3% (7·1–12·2) 15·9% (14·4–17·5)
Types 16 or 18 1·2% (0·3–4·6) 6·3% (4·0–9·9) 6·9% (5·1–9·4) 4·7% (3·4–6·3) 2·6% (1·5–4·5) 4·2% (3·4–5·2)
Neisseria gonorrhoeae 0·0% 0·0% 0·2% (0·1–0·7) 0·0% 0·0% <0·1 (0·0–0·1)
Men
Chlamydia trachomatis 0·0% 0·5% (0·1–2·2) 3·4% (2·2–5·2) 1·0% (0·5–1·9) 0·3% (0·0–2·1) 1·1% (0·7–1·6)
Human papillomavirus*
High-risk types 4·5% (1·9–10·3) 4·0% (2·0–7·9) 8·6% (6·4–11·7) 9·2% (6·6–12·6) 8·8% (5·8–13·3) 8·4% (6·8–10·4)
Types 16 or 18 0·6% (0·1–4·0) 0·9% (0·2–3·5) 2·7% (1·6–4·7) 2·6% (1·7–4·1) 2·2% (1·1–4·5) 2·3% (1·7–3·2)
Neisseria gonorrhoeae 0·0% 0·0% 0·1% (0·0–0·6) 0·0% 0·0% <0·1 (0·0–0·1)
Denominator† (unweighted, weighted)
Women‡ 171, 84 224, 130 597, 383 1146, 809 527, 878 2665, 2284
Men‡ 150, 91 193, 143 497, 391 693, 807 352, 835 1885, 2266
Data are % (95% CI), unless otherwise indicated. *Detection rates of human papillomavirus in urine are lower in men than women. †Denominators shown are for Chlamydia trachomatis; denominators for other 
infections vary slightly. ‡Participants who reported at least one partner, with urine test results.
Table 1: Prevalence of Chlamydia trachomatis, human papillomavirus, and Neisseria gonorrhoeae in urine in participants aged 16–44 years, by age group and sex
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have reported a chlamydia test in the past year than men 
(adjusted OR 2·55, 95% CI 2·13–3·07; table 3). The 
proportions of women and men tested in England were 
signiﬁ cantly higher than those tested in Scotland or 
Wales (table 3). Proportions of individuals testing did not 
diﬀ er by area-level deprivation (table 3). Participants with 
higher numbers of partners in the past year were more 
likely to report testing than were those with low partner 
numbers, as were those with a new partner in the past 
year (data not shown). However, of individuals aged 
16–44 years who had detectable chlamydia in their urine 
most had not had a chlamydia test (66·4%, 95% CI 
55·1%–76·1%), or attended a sexual health clinic (78·7%, 
68·3%–86·4%) in the past year.
Of participants aged 16–24 years who reported at least 
one partner over the lifetime, 3·0% (2·2–4·0) of women 
and 2·0% (1·3–3·0) of men had been diagnosed with 
chlamydia in the past year. We estimated an annual rate of 
chlamydia diagnosis of 2016 (95% CI 1545–2627) per 
100 000 population aged 16–24 years in England. When we 
compared Natsal-2 and Natsal-3, we noted large increases 
in the proportion of participants aged 16–24 years who 
reported being diagnosed with chlamydia in the past 
5 years: from 1·5% (1·2–1·8) to 4·1% (3·6–4·7) in women 
and from 0·8% (0·5–1·1) to 4·0% (3·4–4·8) in men. 
However, in Natsal-2 compared with Natsal-3, prevalence 
of chlamydia in urine in young people aged 18–24 years 
was broadly similar in women (3·1% [1·8–5·2] vs 3·2% 
[2·2–4·6], and men (2·9% [1·3–6·3] vs 2·6% [1·7–4·0]).
High-risk HPV was detected in the urine of 527 
(15·9%) women and 164 (8·4%) men (table 1). The 
weighted age-speciﬁ c prevalence diﬀ ered in women and 
men: from age 20 onwards, prevalence reduced with age 
in women, but remained stable in men (table 1). The 
prevalence of HPV types 16 and 18 was roughly a quarter 
of that of all high-risk HPV (table 1). Increasing numbers 
of partners without condom use in the past year were 
associated with high-risk HPV in both women and men 
(table 4). Prevalence of high-risk HPV in participants 
aged 18–44 was similar in Natsal-3 and Natsal-2: 15·9% 
Women Men Denominator† 
unweighted, weighted
% (95% CI) OR AOR* 95% CI % (95% CI) OR AOR* 95% CI Women Men
All ages 1·5% (1·1–2·0) ·· ·· ·· 1·1% (0·7–1·6) ·· ·· ·· 2665, 2284 1885, 2266
Age (years) ·· p=0·0026 p=0·0135 ·· ·· p=0·0002 p=0·0007 ··
16–19 3·8% (2·2–6·3) 1·00 1·00 ·· 0·3% (0·1–1·3) 1·00 1·00 ·· 395, 214 343, 234
20–24 2·7% (1·7–4·2) 0·71 0·75 0·36–1·57 3·4% (2·2–5·2) 10·55 11·11 2·42–50·93 597, 383 497, 391
25–34 1·5% (0·9–2·5) 0·40 0·45 0·21–0·97 1·0% (0·5–1·9) 2·97 3·39 0·70–16·40 1146, 809 693, 807
35–44 0·3% (0·1–1·3) 0·07 0·09 0·02–0·49 0·3% (0·0–2·1) 0·91 1·35 0·10–18·61 527, 878 352, 835
IMD (quintiles)‡ ·· p=0·0070 p=0·0078 ·· ·· p=0·0014 p=0·0028 ··
1–2 (least deprived) 0·6% (0·2–1·2) 1·00 1·00 ·· 0·5% (0·2–1·2) 1·00 1·00 ·· 906, 806 679, 838
3 1·4% (0·7–2·8) 2·51 2·65 0·92–7·63 0·4% (0·1–1·1) 0·74 0·73 0·18–3·00 521, 458 369, 466
4–5 (most deprived) 2·2% (1·5–3·2) 4·07 4·01 1·67–9·63 1·9% (1·2–2·9) 3·69 3·42 1·28–9·16 1238, 1021 837, 962
Number of sexual partners in the 
past year§
·· p=0·0006 P=0·1284 ·· ·· p<0·0001 p=0·0013 ··
0–1 1·1% (0·7–1·6) 1·00 1·00 ·· 0·6% (0·4–1·1) 1·00 1·00 ·· 2001, 1883 1274, 1731
2 3·2% (1·7–5·7) 3·03 1·97 0·90–4·31 0·7% (0·2–2·3) 1·09 0·78 0·19–3·15 290, 188 244, 223
≥3 3·7% (2·1–6·3) 3·53 1·95 0·91–4·20 4·0% (2·2–6·9) 6·42 4·86 1·84–12·80 354, 197 358, 300
Number of sexual partners without 
a condom in the past year§¶
·· p<0·0001 p=0·0101|| ·· ·· p<0·0001 p<0·0001|| ··
0|| 1·1% (0·5–2·2) 1·00 1·00 ·· 0·2% (0·0–0·7) 1·00 1·00 ·· 469, 428 425, 494
1 1·1% (0·7–1·7) 1·04 1·10 0·46–2·63 0·7% (0·4–1·2) 4·30 5·96 1·30–27·36 1806, 1629 1111, 1486
≥2 5·3% (3·3–8·3) 5·10 3·09 1·20–7·96 4·0% (2·4–6·6) 25·34 22·37 5·04–99·24 355, 199 322, 264
Age at ﬁ rst sex (years)** ·· p=0·0717 p=0·8631 ·· ·· p=0·0997 p=0·7618
≥16 1·3% (0·9–1·8) 1·00 1·00 ·· 0·9% (0·5–1·5) 1·00 1·00 ·· 1733, 1652 1160, 1520
<16 2·1% (1·4–3·1) 1·66 1·05 0·62–1·77 1·6% (1·0–2·5) 1·89 1·14 0·50–2·60 901, 608 692, 709
Ever had same-sex experience?†† ·· p=0·2412 p=0·1251 ·· ·· p=0·1272 p=0·0705 ··
No 1·5% (1·1–2·1) 1·00 1·00 ·· 1·1% (0·8–1·6) 1·00 1·00 ·· 2366, 2088 1748, 2144
Yes 0·8% (0·3–2·3) 0·51 0·40 0·12–1·29 0·2% (0·0–1·7) 0·21 0·15 0·02–1·17 299, 197 137, 121
OR=odds ratio. AOR=adjusted odds ratio. IMD=Index of Multiple Deprivation. *Adjusted for age, IMD quintiles, and number of sexual partners in the past year. †Participants who reported at least one partner, 
with a urine test result. ‡A multidimensional measure of area (neighbourhood)-level deprivation based on the participant’s postcode. We adjusted IMD scores for England, Scotland, and Wales before they were 
combined and assigned to quintiles, with use of a method by Payne and Abel.26 §Includes both opposite-sex and same-sex partners. ¶Number of partners without a condom in the past year is adjusted for age 
and IMD only, because of colinearity with number of sexual partners in the past year. ||Includes individuals with no partners in the past year. **Age at ﬁ rst heterosexual intercourse or ﬁ rst same-sex experience 
involving genital contact. ††Same-sex experience involving genital contact.
Table 2: Risk factors for Chlamydia trachomatis in urine in participants aged 16–44 years, by sex 
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(95% CI 14·3–17·6) vs 16·0% (14·2–18·0) in women and 
8·6% (6·9–10·7) vs 9·9% (8·2–11·9) in men.
Of women eligible for the HPV catch-up immunisation 
programme, 61·5% reported completing the three-dose 
vaccination course (table 3). Vaccination coverage was 
lowest in individuals from the most deprived areas and 
in those with more partners (table 3). Prevalence of HPV 
types 16 and 18 in women aged 18–20 years was 5·8% 
Women Men Denominator 
(unweighted, weighted)
% (95% CI) Crude OR AOR* 95% CI % (95% CI) Crude OR AOR* 95% CI Women Men
Reported testing for Chlamydia trachomatis in the past year in people aged 16–24 years†
All aged 16–24 years 54·2% (51·4–56·9) ·· ·· ·· 34·6% (31·8–37·4) ·· ·· ·· 1736, 966 1375, 1003
By age group (years) ·· p=0·1637 p=0·7670 ·· ·· p=0·0019 p=0·0023 ··
16–19 56·6% (52·5–60·6) 1·00 1·00 ·· 40·4% (35·8–45·1) 1·00 1·00 ·· 672, 343 582, 374
20–24 52·8% (49·3–56·3) 0·86 0·97 0·77–1·21 31·1% (27·8–34·7) 0·67 0·67 0·52–0·87 1064, 623 793, 629
By IMD quintile‡ ·· p=0·9938 p=0·9492 ·· ·· p=0·8863 p=0·8303 ··
1–2 (least deprived) 54·2% (49·7–58·7) 1·00 1·00 ·· 34·5% (30·1–39·2) 1·00 1·00 ·· 595, 338 509, 369
3 54·4% (48·0–60·7) 1·01 1·05 0·76–1·44 33·3% (27·4–39·9) 0·95 0·90 0·62–1·29 324, 189 263, 183
4–5 (most deprived) 54·0% (49·9–58·1) 0·99 1·00 0·78–1·28 35·2% (31·2–39·4) 1·03 0·98 0·74–1·30 817, 439 603, 450
By number of sexual 
partners in the past year§
·· p<0·0001 p<0·0001 ·· ·· p<0·0001 p<0·0001 ··
0–1¶ 46·6% (43·3–49·9) 1·00 1·00 ·· 26·0% (22·7–29·6) 1·00 1·00 ·· 1096, 624 768, 568
2 65·2% (59·0–70·9) 2·15 2·13 1·58–2·86 40·3% (33·2–47·7) 1·92 1·88 1·32–2·67 275, 143 251, 185
≥3 71·8% (65·4–77·4) 2·91 2·88 2·07–4·02 50·8% (44·8–56·8) 2·93 2·87 2·11–3·91 345, 188 340, 237
By country ·· p<0·0001 p<0·0001 ·· ·· p=0·0001 p<0·0001 ··
England 57·1% (54·1–60·1) 1·00 1·00 ·· 37·3% (34·3–40·3) 1·00 1·00 ·· 1452, 823 1181, 859
Scotland 32·4% (24·2–41·8) 0·36 0·34 0·23–0·51 22·2% (13·6–34·1) 0·48 0·44 0·24–0·82 178, 91 111, 89
Wales 45·6% (36·2–55·3) 0·63 0·60 0·38–0·96 12·8% (6·7–23·0) 0·25 0·21 0·10–0·44 106, 52 83, 55
Reported completion of a three-dose course of HPV vaccination in participants eligible for the catch–up programme||
All eligible 61·5% (58·2–64·7) ·· ·· ·· ·· ·· ·· ·· 1050, 562 ··
By IMD quintile‡ ·· p<0·0001 p=0·0001 ·· ·· ·· ·· ·· ·· ··
1–2 (least deprived) 69·9% (64·6–74·7) 1·00 1·00 ·· ·· ·· ·· ·· 393, 210 ··
3 63·3% (55·4–70·6) 0·74 0·71 0·47–1·07 ·· ·· ·· ·· 209, 116 ··
4–5 (most deprived) 53·1% (48·1–58·0) 0·49 0·50 0·36–0·68 ·· ·· ·· ·· 448, 236 ··
By number of sexual 
partners over the lifetime§
·· p<0·0001 p=0·0090 ·· ·· ·· ·· ·· ··
0 75·5% (68·3–81·5) 1·00 1·00 ·· ·· ·· ·· ·· 205, 109 ··
1 65·6% (57·5–72·8) 0·62 0·69 0·42–1·15 ·· ·· ·· ·· 203, 113 ··
2 62·5% (53·3–70·8) 0·54 0·63 0·37–1·08 ·· ·· ·· ·· 147, 77 ··
≥3 53·8% (48·9–58·7) 0·38 0·47 0·30–0·74 ·· ·· ·· ·· 488, 260 ··
Reported testing for HIV in the past 5 years**
All aged 16–44 years 27·6% (26·1–29·1) ·· ·· ·· 16·9% (15·5–18·5) ·· ·· ·· 4967, 3458 3429, 3502
By age group (years) ·· p<0·0001 p<0·0001 ·· p<0·0001 p<0·0001 ··
16–24 29·3% (26·9–31·8) 1·00 1·00 ·· 14·0% (12·0–16·2) 1·00 1·00 1636, 911 1315, 958
25–34 36·1% (33·8–38·5) 1·36 1·87 1·59–2·21 24·3% (21·7–27·1) 1·98 2·85 2·24–3·62 2236, 1235 1372, 1229
35–44 18·4% (16·0–21·0) 0·54 0·88 0·71–1·09 12·2% (9·9–14·9) 0·86 1·69 1·22–2·34 1095, 1312 742, 1315
By IMD quintile‡ ·· p=0·0096 p=0·0096 ·· ·· p=0·3794 p=0·6897 ··
1–2 (least deprived) 24·7% (22·4–27·0) 1·00 1·00 ·· 15·9% (13·6–18·6) 1·00 1·00 1708, 1257 1241, 1299
3 26·8% (23·7–30·2) 1·12 1·14 0·93–1·40 16·1% (13·4–19·2) 1·01 1·04 0·78–1·40 957, 683 656, 681
4–5 (most deprived) 30·4% (28·2–32·6) 1·33 1·29 1·10–1·52 18·1% (15·9–20·6) 1·17 1·12 0·87–1·44 2302, 1518 1532, 1523
By number of sexual 
partners in the past 5 years§
·· p<0·0001 p<0·0001 ·· ·· p<0·0001 p<0·0001 ··
0–1 21·8% (20·0–23·7) 1·00 1·00 ·· 9·1% (7·5–11·0) 1·00 1·00 ·· 2493, 1981 1372, 1713
2–4 30·3% (27·7–33·0) 1·56 1·47 1·24–1·75 17·0% (14·4–19·8) 2·03 2·31 1·72–3·10 1520, 926 1055, 960
5–9 44·8% (40·1–49·6) 2·91 2·67 2·12–3·37 26·4% (22·2–31·0) 3·57 4·27 3·06–5·94 589, 343 538, 442
≥10 49·2% (42·6–55·8) 3·48 3·11 2·30–4·20 41·6% (36·4–47·0) 7·09 8·49 6·12–11·76 313, 167 435, 358
(Continues on next page)
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(95% CI 3·9–8·6), which was lower than that noted 
before introduction of the immunisation programme in 
Natsal-2 (11·3% [6·8–18·2]; age-adjusted OR 0·44 
[0·21–0·94]). Prevalence of HPV types 16 or 18 was 
likewise reduced in men in Natsal-3 (1·1% [0·4–3·0]) 
compared with those in Natsal-2 (5·0% [1·7–13·6]; age-
adjusted OR 0·20 [0·04–0·93]).
Three women and one man had urine tests that were 
positive for gonorrhoea, giving a weighted prevalence of 
less than 0·1% in both women and men aged 16–44 years 
Women Men Denominator 
(unweighted, weighted)
% (95% CI) Crude OR AOR* 95% CI % (95% CI) Crude OR AOR* 95% CI Women Men
(Continued from previous page)
Among target groups††
People who attended a 
GUM or sexual health 
clinic in the past 5 years
58·3% (55·3–61·4) ·· ·· ·· 50·8% (46·4–55·1) ·· ·· ·· 1270, 737 811, 676
Those diagnosed with an 
STI in the past 5 years‡‡
68·3% (62·4–73·6) ·· ·· ·· 54·7% (47·1–62·1) ·· ·· ·· 376, 210 243, 214
Women who had 
attended antenatal 
services in the past 
5 years
47·9% (44·7–51·0) ·· ·· ·· ·· ·· ·· ·· 1326, 872 ··
Women who had had an 
abortion in the past 
5 years§§
48·8% (42·5–55·2) ·· ·· ·· ·· ·· ·· ·· 310, 164 ··
Men who had had sex 
with a man in the past 
5 years
·· ·· ·· ·· 51·6% (41·1–61·9) ·· ·· ·· ·· 134, 112
People of black African 
ethnic origin
46·1% (35·6–57·0) ·· ·· ·· 43·9% (30·3–58·6) ·· ·· ·· 96, 75 71, 82
Reported attendance at sexual health clinics in the past 5 years**
All aged 16–44 years 21·4% (20·1–22·7) ·· ·· ·· 19·6% (18·2–21·2) ·· ·· ·· 5234, 3651 3546, 3624
By age group (years) ·· p<0·0001 p<0·0001 ·· p<0·0001 p<0·0001 ··
16–24 43·8% (41·1–46·5) 1·00 1·00 ·· 31·4% (28·6–34·4) 1·00 1·00 ·· 1701, 947 1353, 987
25–34 21·3% (19·4–23·4) 0·35 0·55 0·46–0·66 23·6% (21·3–26·1) 0·67 0·97 0·79–1·22 2365, 1306 1418, 1269
35–44 6·3% (5·0–7·8) 0·09 0·19 0·14–0·25 7·5% (5·8–9·7) 0·18 0·37 0·26–0·51 1168, 1398 775, 1368
By IMD quintile‡ p<0·0001 p=0·0007 ·· p=0·0184 p=0·1682 ··
1–2 (least deprived) 18·3% (16·5–20·3) 1·00 1·00 ·· 17·0% (14·8–19·5) 1·00 1·00 ·· 1791, 1327 1279, 1338
3 19·9% (17·3–22·9) 1·12 1·10 0·86–1·40 20·2% (17·1–23·7) 1·22 1·25 0·94–1·66 1022, 726 682, 709
4–5 (most deprived) 24·6% (22·7–26·6) 1·45 1·41 1·18–1·70 21·6% (19·5–23·9) 1·36 1·22 0·97–1·54 2421, 1598 1585, 1576
By number of sexual 
partners in the 
past 5 years§
·· p<0·0001 p<0·0001 ·· p<0·0001 p<0·0001 ··
0–1 7·7% (6·7–8·9) 1·00 1·00 ·· 5·8% (4·8–7·1) 1·00 1·00 ·· 2644, 2113 1439, 1795
2–4 30·5% (28·0–33·2) 5·24 3·77 3·09–4·59 24·3% (21·5–27·4) 5·20 4·12 3·11–5·44 1625, 992 1093, 1001
5–9 55·1% (50·4–59·7) 14·66 8·88 6·88–11·46 34·9% (30·3–39·9) 8·69 6·37 4·64–8·74 621, 359 554, 453
≥10 65·6% (59·2–71·4) 22·73 12·11 8·65–16·96 55·9% (50·6–61·1) 20·54 15·36 11·15–21·16 320, 171 441, 359
In people diagnosed with 
an STI in the past 5 years‡‡
83·7% (79·1–87·4) ·· ·· ·· 85·4% (79·4–89·8) ·· ·· ·· 322, 220 213, 215
In men who had had sex 
with a man in the past 
5 years
·· ·· ·· ·· 45·0% (35·0–55·5) ·· ·· ·· ·· 136, 115
OR=odds ratio. AOR=adjusted odds ratio. IMD=Index of Multiple Deprivation. GUM=genitourinary medicine. *ORs adjusted for age, adjusted IMD, and number of sexual partners in the past 1 or 5 years. †Denominator is 
individuals aged 16–24 years who reported at least one partner over the lifetime. ‡A multidimensional measure of area (neighbourhood)-level deprivation based on the participant’s postcode. We adjusted IMD scores for 
England, Scotland, and Wales before they were combined and assigned to quintiles, with use of a method by Payne and Abel.26 §Includes both opposite-sex and same-sex partners. ¶Testing was lower in individuals with 
no partners than in those who had had one partner in the past year: 21·5% (95% CI 11·2–37·4) vs 47·9% (44·4–51·3) for women and 5·7% (2·3 –13·7) vs 28·0% (24·4 –31·9) for men. Because the unweighted denominators 
for individuals with no partners were small (48 women and 73 men), we combined the 0 and 1 categories. ||Denominator is women eligible for human papillomavirus vaccination catch-up programme—ie, those born 
between Sept 1, 1990, and Aug 31, 1995 who reported some sexual experience. **Denominator is participants aged 16–44 years who reported at least one partner over the lifetime. ††Target groups identiﬁ ed in UK 
National Guidelines for HIV Testing 2008.16 ‡‡Diagnosed with chlamydia, gonorrhoea, herpes, genital warts, trichomonas, non-speciﬁ c or non-gonococcal urethritis, or syphilis. §§Abortion in the past 5 years was used as a 
proxy for attending a clinic for termination of pregnancy.
Table 3: Uptake of sexual health interventions and services, by sex
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(table 1). These participants were all aged 20–24 years 
and reported sex with at least two partners in the past 
year without use of condoms. All four had chlamydia 
co-infection.
Three women and six men tested positive for HIV 
antibody, giving estimated prevalences of 0·1% (95% CI 
0·0–0·4) in women and 0·2% (0·1–0·6) in men. Of these 
participants, ﬁ ve were white British men who reported 
having had sex with a man over the lifetime, giving an 
estimated weighted prevalence of 2·8% (1·1–6·9) in this 
group. The three women and one man who did not report 
any same-sex experiences and tested HIV positive were all 
of black ethnic origin; the prevalence estimate in this group 
was 2·8% (1·0–7·7). All eight participants who answered 
the question reported having had an HIV test in the past 
5 years and receiving the result. None of the HIV-positive 
participants reported a history of injecting drug use.
More women than men reported HIV testing in the past 
5 years (table 3). Testing was highest in individuals aged 
25–34 years, in those with more sexual partners, in those 
who had attended a sexual health clinic, in those who had 
been diagnosed with an STI in the past 5 years, in people 
of black African ethnic origin, and in men who had sex 
with men in the past 5 years. The proportion of men who 
had sex with men who had HIV tests increased with 
increasing partner numbers (data not shown), reaching 
84·5% (95% CI 69·4–92·9) in men reporting ﬁ ve or more 
male partners in the past 5 years. The proportion of 
participants reporting having had an HIV test in the past 
5 years was higher in Natsal-3 (27·6% in women and 
16·9% in men; table 3) than in Natsal-2 (8·7% vs 9·2%) 
and Natsal-1 (10·5% vs 6·6%; appendix). HIV testing was 
generally higher with increasing numbers of sexual 
partners and in groups speciﬁ cally targeted for testing 
(ﬁ gure 1), with increases in testing mostly occurring in the 
past 10 years.
In the past 5 years, roughly a ﬁ fth of women and men 
reported attendance at a sexual health clinic, with 
Women Men Denominator† 
unweighted, weighted
% (95% CI) OR AOR* 95% CI % (95% CI) OR AOR* 95% CI Women Men
All ages 15·9% (14·4–17·5) ·· ·· ·· 8·4% (6·8–10·4) ·· ·· ·· 2569, 2189 1799, 2165
Age (years) ·· p<0·0001 p<0·0001 ·· ·· p=0·0705 p=0·0404 ·· ·· ··
16–19 24·4% (20·0–29·3) 1·00 1·00 ·· 4·2% (2·5–7·1) 1·00 1·00 ·· 377, 203 326, 222
20–24 26·6% (22·8–30·8) 1·13 1·38 0·97–1·97 8·6% (6·4–11·7) 2·16 2·20 1·15–4·17 580, 370 475, 371
25–34 15·6% (13·4–18·2) 0·58 0·83 0·59–1·18 9·2% (6·6–12·6) 2·30 2·44 1·27–4·70 1108, 779 661, 766
35–44 9·3% (7·1–12·2) 0·32 0·53 0·34–0·80 8·8% (5·8–13·3) 2·21 2·46 1·19–5·10 504, 837 337, 805
IMD (quintiles)‡ ·· p=0·0238 p=0·0508 ·· ·· p=0·5621 p=0·5781 ·· ·· ··
1–2 (least deprived) 13·5% (11·2–16·1) 1·00 1·00 ·· 7·6% (5·5–10·5) 1·00 1·00 ·· 873, 778 653, 808
3 15·0% (11·8–18·7) 1·13 1·16 0·81–1·64 7·6% (4·2–13·3) 0·99 0·99 0·48–2·04 502, 439 356, 452
4–5 (most deprived) 18·3% (15·9–20·9) 1·43 1·40 1·07–1·84 9·6% (7·0–13·0) 1·28 1·28 0·78–2·10 1194, 973 790, 904
Number of sexual partners in 
the past year§
·· p<0·0001 p<0·0001 ·· ·· p=0·3639 p=0·2841 ·· ·· ··
0–1 12·1% (10·6–13·7) 1·00 1·00 ·· 8·0% (6·1–10·5) 1·00 1·00 ·· 1925, 1802 1213, 1651
2 26·1% (20·3–32·9) 2·57 2·18 1·51–3·14 8·3% (5·2–13·0) 1·05 1·13 0·62–2·07 276, 179 237, 217
≥3 41·2% (35·1–47·7) 5·11 3·95 2·87–5·45 11·1% (7·6–15·9) 1·44 1·53 0·90–2·58 349, 194 340, 285
Number of sexual partners 
without a condom in the 
past year§¶
·· p<0·0001 p<0·0001|| ·· ·· p=0·0219 p=0·0141|| ·· ·· ··
0|| 11·3% (8·5–14·9) 1·00 1·00 ·· 5·2% (2·8–9·6) 1·00 1·00 ·· 451, 408 407, 473
1 14·0% (12·3–15·8) 1·27 1·32 0·94–1·87 8·8% (6·7–11·4) 1·73 1·65 0·78–3·47 1739, 1564 1060, 1418
≥2 40·1% (34·0–46·5) 5·23 4·24 2·79–6·44 13·4% (9·3–19·0) 2·80 2·88 1·36–6·11 347, 193 305, 251
Age at ﬁ rst sex (years)** ·· p<0·0001 p=0·1580 ·· p=0·2137 p=0·2569 ·· ·· ··
≥16 14·2% (12·5–16·2) 1·00 1·00 ·· 7·7% (5·7–10·4) 1·00 1·00 ·· 1665, 1577 1105, 1451
<16 20·9% (18·1–24·1) 1·60 1·20 0·93–1·55 10·0% (7·6–13·0) 1·32 1·29 0·83–2·00 874, 587 663, 678
Ever had same-sex experience?†† ·· p=0·0309 p=0·6037 ·· ·· p=0·3272 p=0·1578 ·· ·· ··
No 15·4% (13·8–17·1) 1·00 1·00 ·· 8·6% (6·9–10·7) 1·00 1·00 ·· 2277, 1998 1672, 2052
Yes 21·2% (16·2–27·3) 1·48 1·11 0·74–1·66 6·0% (2·9–11·8) 0·67 0·55 0·24–1·26 292, 192 127, 113
OR=odds ratio. AOR=adjusted odds ratio. IMD=Index of Multiple Deprivation. *Adjusted for age, IMD quintiles, and number of sexual partners in the past year. †Participants who reported at least one partner, 
with a urine test result. ‡A multidimensional measure of area (neighbourhood)-level deprivation based on the participant’s postcode· We adjusted IMD scores for England, Scotland, and Wales before they were 
combined and assigned to quintiles, with use of a method by Payne and Abel.26 §Includes both opposite-sex and same-sex partners. ¶Number of partners without a condom in the past year is adjusted for age 
and IMD only, because of colinearity with number of sexual partners in the past year. ||Includes individuals with no partners in the past year. **Age at ﬁ rst heterosexual intercourse or ﬁ rst same-sex experience 
involving genital contact. ††Same-sex experience involving genital contact.
Table 4: Risk factors for high-risk human papillomavirus in urine among in participants aged 16–44 years, by sex
See Online for appendix
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attendance highest in the youngest age group, in those 
with higher numbers of partners, and in women from 
the most deprived areas (table 3). More than 80% of 
participants reporting an STI diagnosis in the past 
5 years had attended a sexual health clinic (table 3). 
Figure 2 shows attendance at sexual health clinics in the 
past 5 years in women and men aged 16–44 years across 
the three Natsal surveys, by number of partners and age 
group. We noted a signiﬁ cant increase in clinic 
attendance over the three surveys, with increasing 
attendance seen in all subgroups (appendix).
Discussion
Findings from this large population-based survey show 
that the four STIs are distributed heterogeneously in the 
British population. High-risk HPV was the most 
prevalent infection, followed by chlamydia; HIV and 
gonorrhoea were uncommon. Although STI risk 
increased with increasing partner numbers, most of the 
chlamydia and HPV infections were in individuals who 
did not have many recent partners because most of the 
population had only had one partner in the past year.20 
For chlamydia and HPV, broad population-wide 
interventions are needed. By contrast, we show that 
gonorrhoea and HIV were restricted to a small proportion 
of the population who had high risk factors, including 
other STIs, supporting targeted interventions. STI 
transmission is a function of individual and partnership 
risks, as shown by the sex diﬀ erences in the age 
distribution of chlamydia, which is related to patterns of 
sexual mixing, because younger women, on average, 
have older male partners.29
STI-speciﬁ c interventions that take account of the 
epidemic phase30 are key components of STI prevention 
strategies. More focused interventions that include 
outbreak investigation and contact tracing might be 
more cost-eﬀ ective than generalised screening for rare 
infections. The very low population prevalence of 
gonorrhoea allays concerns about widespread or 
asymptomatic infection in the community. The 
prevalence of gonorrhoea was substantially higher in 
people testing positive for chlamydia than it was in the 
general population, suggesting that, in addition to 
outbreak investigation, gonorrhoea testing in people 
with chlamydia identiﬁ ed through population screening 
might be an appropriate strategy.
Survey participants and those providing urine might 
not be fully representative of the general population, 
despite our best eﬀ orts to adjust for known biases. To 
minimise non-participation bias, we weighted Natsal-3 
Figure 1: Change over time in reported HIV testing in the past 5 years, by number of sexual partners (A, B) and target group (C, D)
Denominator is individuals aged 16–44 years who reported at least one sexual partner over the lifetime. The appendix shows the proportions, 95% CIs, and p values 
for the diﬀ erence between Natsal-3 and Natsal-2.
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data to correct for diﬀ erential selection probabilities and 
for diﬀ erential non-response (by comparing with census 
data).18–20 Application of the urine selection and non-
response weights further reduced participation bias. As 
discussed elsewhere,18,20 to minimise reporting bias, we 
included an extensive development phase17 and used 
computer-assisted self-interview for sensitive questions.
In this population-based study, we undertook tests on 
urine rather than genital specimens for practicality and 
acceptability. We recognise that urine is a suboptimum 
specimen for the detection of some STIs, particularly HPV 
in men, and that prevalence might be underestimated, 
although we are able to assess risk factors. Comparisons of 
urine prevalence estimates  between Natsal-2 and Natsal-3 
should be made with caution, in view of diﬀ erences in 
methods of sample collection, preparation and storage, 
chlamydia diagnostic tests, and because the surveys were 
not powered to detect changes in prevalence. Trends in STI 
prevalence should be considered in the context of possible 
changes in sexual behaviour over time. Between Natsal-2 
and Natsal-3, modest increases in some risk behaviours 
have taken place (including increases in partner numbers) 
in women, but evidence shows some reduction in men, by 
contrast with the increases in both sexes noted between 
Natsal-1 and Natsal-2.20
Compared with Natsal-2, which tested urine from a 
sample of participants aged 18–44 years, in Natsal-3 we 
extended the age range to include 16–17-year-olds. This 
change improved prevalence estimates in the younger 
age groups, who have the highest prevalence and greatest 
risk of sequelae and are therefore the age groups at whom 
interventions are targeted. People remain sexually active 
into older age,20 including having new partners, which 
means that STI risk continues. Surveillance data show 
that the rate of acute STIs diagnosed in sexual health 
clinics in individuals aged 20–24 years is almost 20 times 
higher than that in those aged 44–59 years (4278 per 
100 000 population vs 227 per 100 000 population in 2012).2 
Although recent reports have shown increases in some 
diagnosed STIs in older age groups, the absolute rates are 
very low.2 Therefore, even a population-based survey of 
more than 15 000 participants, as in Natsal-3, would not 
have suﬃ  cient power to estimate STI prevalence in those 
older than 44 years with useful precision.
Attendance at sexual health clinics and uptake of HIV 
testing have increased substantially in the past two decades. 
Furthermore, many sexually active young adults reported 
having had a chlamydia test in the past year. Although it is 
reassuring that large and increasing proportions of the 
population at highest risk are accessing services and 
testing, many people have still not done so. For example, 
two-thirds of the participants in whom chlamydia was 
detected in our study did not report a test in the past year, 
and more than three-quarters had not attended a sexual 
health service in the past year. Roughly half of the sexually 
active men who had sex with men in our study had tested 
for HIV in the past 5 years and only  27% (95% CI 19–37) in 
the past year—far less than the recommendation to test all 
men in this group annually.16 Convenience surveys of men 
who have sex with men have reported that 50–60% of men 
have been tested in the past year,31,32 whereas surveillance 
data estimate about 10%.33 Our results provide a valuable 
population-based estimate by including men who have sex 
with men who do not necessarily identify as gay or use 
sexual health services.
One in ﬁ ve sexually active participants reported 
attendance at a sexual health clinic in the past 5 years, 
which is consistent with estimates from clinic surveillance 
data (overall 19·9% of women and 17·2% of men, with age-
speciﬁ c proportions also similar).34 This ﬁ nding suggests 
that a minimum amount of misclassiﬁ cation bias took 
place when individuals answered the revised question in 
Natsal-3, despite the broad range of settings used for sexual 
health services in 2010. 80% of people with an STI diagnosis 
in the past 5 years reported attendance at a sexual health 
clinic, suggesting that in most cases, treatment for STIs 
occurs in specialist services. Uptake of antenatal HIV 
testing, measured from unlinked anonymous surveillance, 
was 97% in 2011;33 however, the reporting of this testing was 
much lower in Natsal-3 (48%). Although this proportion is 
signiﬁ cantly higher than the 15% reported in Natsal-2, both 
Figure 2: Change over time in reported attendance at sexual health clinics in the past 5 years, by age group 
(A, B) and number of partners (C, D)
Denominator is individuals aged 16–44 years who reported at least one sexual partner over the lifetime. The 
appendix shows the proportions, 95% CIs, and p values for the diﬀ erence between Natsal-3 and Natsal-2.
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ﬁ gures probably show women’s low awareness or poor 
recall of having been tested, in the context of a large variety 
of screening tests in an antenatal clinic.
Reducing inequalities is a key principle of the National 
Strategy for Sexual Health and HIV.13 Measurement of 
inequalities is complex. Diﬀ erent indicators might 
result in diﬀ erent ﬁ ndings, as shown in analyses of 
sexual behaviours and attitudes by area-level deprivation, 
educational attainment, and National Statistics Socio-
economic Classiﬁ cation (NS-SEC) in participants aged 
16–74 years in Natsal-3.20 Similarly, a review examining 
the association between socioeconomic circumstances 
and chlamydia prevalence in various countries showed 
substantial variations, dependent on the measure used.35 
The IMD at small area level has seven domains (income, 
employment, health, education, housing and services, 
crime, and living environment).26 We used this index as 
a multidimensional measure of social deprivation, in 
recognition that individual-level indicators, such as 
NS-SEC, can be diﬃ  cult to deﬁ ne and interpret, 
especially in young people. We recorded a strong 
association between area-level deprivation and 
chlamydia prevalence, but no association with 
chlamydia testing uptake, suggesting that increases in 
the levels and intensity of testing in the most deprived 
areas might be needed.
The rise in chlamydia diagnoses, as shown in surveillance 
data,2 is better explained by increases in ascertainment 
through increased service use and testing than by increases 
in sexual risk behaviour.20 Although the estimated rate of 
chlamydia diagnoses is approaching the Public Health 
Outcomes Framework target of 2300 per 100 000 
population in England,27 increased chlamydia testing is 
needed. In view of the levels of chlamydia testing, the 
increase in diagnoses, and estimates from mathematical 
models,36 we might expect to see reductions in chlamydia 
prevalence. Comparisons between prevalence estimates 
from Natsal-25 and Natsal-3 need to consider the caveats 
mentioned above. Present prevalence might have been 
higher without improved chlamydia control.
In both Natsal-26 and Natsal-3, the prevalence of high-
risk HPV was higher in women than men in all age 
groups partly due to the lower sensitivity of urine-based 
testing to identify true genital infection with HPV in men 
compared with women.37 The reported uptake of HPV 
vaccination in participants eligible for the catch-up 
programme was more than 60%; however, coverage was 
lower in groups at higher risk. We were unable to assess 
uptake of the routine programme (in girls aged 
12–13 years), because very few were old enough to be 
included in Natsal-3 by 2012. However, estimated coverage 
from programme data has been more than 80%, with no 
signiﬁ cant variation by area-level deprivation,38 although 
uptake needs ongoing monitoring. Reduction in the 
prevalence of high-risk HPV types targeted by the vaccine 
is an early measure of the eﬀ ect of the HPV immunisation 
programme. We noted a reduction in the prevalence of 
HPV types 16 and 18 in young women that was of similar 
magnitude to that reported in recent surveillance data.39 
We also recorded a reduction in these HPV types in 
young men. These ﬁ ndings need to be explored in the 
context of the changes in sample collection, other HPV 
types, patterns of sexual mixing, behaviour, and herd 
immunity. In September, 2012, the UK programme 
switched from the bivalent to the quadrivalent vaccine, 
which includes HPV types 6, 11, 16, and 18. Data from 
Australia and the USA, with use of the quadrivalent 
vaccine, have shown reductions in all four of these HPV 
types in women in the target age groups,40,41 and, in a 
further measure of the eﬀ ect of the quadrivalent vaccine, 
in the incidence of genital warts.42
National guidelines recommend expansion of HIV 
testing for all individuals admitted to hospital, and in 
general practice, in regions where diagnosed HIV 
prevalence is greater than 2 per 1000 population (ie, 0·2%) 
in 15–59-year-olds.16 Although the overall HIV prevalence 
was less than this threshold, the prevalence in some 
groups, such as men who have sex with men and those of 
black ethnic origin, was estimated to be more than ten 
times higher than the overall population prevalence. Too 
few people had HIV infection to provide region-speciﬁ c 
Panel: Research in context
Systematic review
While many developed countries have national sexual health services and surveillance,45 few 
population-based surveys (the National Health and Nutrition Examination Survey46 and 
AddHealth 47 in the USA and Contexte de la Sexualité en France48) have included testing for 
sexually transmitted infections (STIs). Natsal-2 included biological sampling, and tested for 
Chlamydia trachomatis, showing a clear association with sexual behaviour, particularly 
multiple sexual partnerships,5 and provided baseline estimates of type-speciﬁ c human 
papillomavirus (HPV) before the introduction of the HPV vaccination programme in 2008.6 
Many large-scale population-based public health interventions are not subject to randomised 
controlled trials and can rely on natural experiments 49 or mathematical modelling to assess 
eﬀ ect.36,50 Comparison within populations and across countries is diﬃ  cult because variations 
might exist in underlying STI epidemiology, health services, surveillance systems, and STI 
control measures. The UK has a network of accessible, conﬁ dential sexual health clinics, a 
National Health Service that is free at the point-of-care, and an STI surveillance system that 
has existed for almost a century. The combination of repeated cross-sectional national 
probability sexual health surveys, with detailed behavioural data and STI testing, surveillance, 
and comprehensive free open-access services, is, to our knowledge, unique.
Interpretation
Our study updates prevalence estimates and risk factors for chlamydia and HPV, and, for the 
ﬁ rst time, reports population prevalences for gonorrhoea and HIV. With use of data from all 
three National Survey of Sexual Attitudes and Lifestyles (Natsal) studies, we show increases in 
reported chlamydia diagnoses and HIV testing, and in attendance at sexual health clinics, 
especially in individuals at highest risk. We also report coverage of HPV catch-up programmes 
and early ﬁ ndings of a reduction in HPV types 16 and 18 in women in the eligible age group. 
Although Natsal is not speciﬁ cally designed or powered to evaluate particular interventions or 
initiatives, especially in subgroups of the population, the surveys allow us to track progress 
and measure some outcomes to complement and validate routinely collected data. 
Furthermore, Natsal provides empirical population-based estimates of prevalence and uptake 
according to risk, and behavioural data to populate mathematical models.
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estimates of prevalence. Although the ﬁ nding that eight of 
the nine HIV-positive participants in Natsal-3 reported 
previous testing is reassuring, we cannot know at what 
stage in their infection, or whether, they were diagnosed. 
National surveillance data show that many people in the 
community have undiagnosed infection, such that many 
present with late-stage disease.33 The HIV-positive 
participants in Natsal-3 all had clearly identiﬁ able risks, 
reinforcing the need to raise awareness of HIV and its 
prevention, particularly in the groups most aﬀ ected. To 
detect HIV both within and outside the main risk groups, 
health professionals should take an appropriate history 
and increase testing in routine clinical practice.
The greatly increased uptake of sexual health services in 
the past decade, particularly in people at increased STI 
risk, is encouraging (panel). Three of the interventions we 
measured are indicators in the Public Health Outcomes 
Framework27 (chlamydia diagnoses rate, HPV 
immunisation, and HIV testing [late diagnoses]) and are 
included in the 2013 Framework for Sexual Health 
Improvement in England.43 This framework, and the 
Sexual Health and Wellbeing Action Plan for Wales 
2010–15,44 also emphasise the need for high-quality 
integrated sexual health services and promotion of 
prevention strategies. At a time of change in the 
organisation and structure of service delivery and 
commissioning, these ﬁ ndings provide empirical evidence 
to inform future sexual health interventions and services.
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